Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2013 by Rachel Yehuda, Bronx VA Medical Center.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
Rachel Yehuda, Bronx VA Medical Center
ClinicalTrials.gov Identifier:
NCT01525680
First received: February 1, 2012
Last updated: November 27, 2013
Last verified: November 2013
  Purpose
This study seeks to examine the efficacy of hydrocortisone administration in the augmentation of the therapeutic effects of Prolonged Exposure (PE) therapy, an empirically tested treatment shown to be effective in the the treatment of posttraumatic stress disorder (PTSD). The augmentation builds on both the translation of neuroscience findings demonstrating the effects of glucocorticoids (GCs) on learning, and on empirical clinical findings from other investigators demonstrating beneficial effects of GCs in reducing traumatic memories in trauma-exposed persons.

Condition Intervention
Post Traumatic Stress Disorder
Other: Hydrocortisone augmented Prolonged Exposure Therapy
Other: Prolonged exposure therapy with placebo administration

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Improving PTSD Outcomes in OIF/OEF Returnees: A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure Therapy"

Resource links provided by NLM:


Further study details as provided by Rachel Yehuda, Bronx VA Medical Center:

Primary Outcome Measures:
  • Clinician Administered PTSD Scale (CAPS) [ Time Frame: week 0 ]
    Assessment of the severity of PTSD symptoms and of diagnosis of PTSD.

  • Clinician Administered PTSD Scale (CAPS) [ Time Frame: week 12 ]
    Assessment of the severity of PTSD symptoms and of diagnosis of PTSD.

  • Clinician Administered PTSD Scale (CAPS) [ Time Frame: week 23 ]
    Assessment of the severity of PTSD symptoms and of diagnosis of PTSD.


Secondary Outcome Measures:
  • Biological measures associated with PTSD [ Time Frame: week 0 ]
    Measures of neuroendocrinology, genotyping, gene expression, and methylation at glucocorticoid receptor.

  • Biological measures associated with PTSD [ Time Frame: week 12 ]
    Measures of neuroendocrinology, genotyping, gene expression, and methylation at glucocorticoid receptor.

  • Biological measures associated with PTSD [ Time Frame: week 23 ]
    Measures of neuroendocrinology, genotyping, gene expression, and methylation at glucocorticoid receptor.

  • MATRICS Consensus Cognitive Battery (MCCB) [ Time Frame: week 0 ]
    Measure of cognitive ability in the following domains: processing speed, attention, working memory (verbal and non-verbal), verbal learning, visual learning, reasoning and problem solving, and social cognition.

  • MATRICS Consensus Cognitive Battery (MCCB) [ Time Frame: week 12 ]
    Measure of cognitive ability in the following domains: processing speed, attention, working memory (verbal and non-verbal), verbal learning, visual learning, reasoning and problem solving, and social cognition.

  • MATRICS Consensus Cognitive Battery (MCCB) [ Time Frame: week 23 ]
    Measure of cognitive ability in the following domains: processing speed, attention, working memory (verbal and non-verbal), verbal learning, visual learning, reasoning and problem solving, and social cognition.

  • Other measures of clinical, psychological, and functional outcome [ Time Frame: week 0 ]
    Measures of symptom severity, trauma-related cognitions, and resiliency.

  • Other measures of clinical, psychological, and functional outcome [ Time Frame: week 12 ]
    Measures of symptom severity, trauma-related cognitions, and resiliency.

  • Other measures of clinical, psychological, and functional outcome [ Time Frame: week 23 ]
    Measures of symptom severity, trauma-related cognitions, and resiliency.


Estimated Enrollment: 60
Study Start Date: April 2011
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Prolonged Exposure therapy with Hydrocortisone Other: Hydrocortisone augmented Prolonged Exposure Therapy
11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
Placebo Comparator: Prolonged Exposure therapy with placebo Other: Prolonged exposure therapy with placebo administration
11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.

  Eligibility

Ages Eligible for Study:   18 Years to 89 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18 to 89
  • Capable of understanding, reading, and writing in English
  • OIF/OEF veteran with criterion-A trauma while deployed
  • Minimum PTSD severity of 60 (CAPS)
  • Unmedicated or on a stable psychotropic regimen (i.e., 1 or more months on the same regimen)

Exclusion Criteria:

  • Lifetime history of psychotropic disorder, bipolar disorder, or obsessive compulsive disorder
  • Moderate or severe traumatic brain injury (TBI)
  • A medical or mental health problem other than PTSD that requires immediate clinical attention
  • Substance abuse or dependence within the last 3 months
  • Suicidal risk (as determined by response of 5 or 6 on the suicidality items of the Montgomery-Asberg Depression Rating Scale (MADRS)) and/or assessed suicide risk on the basis of clinical judgment
  • Persons on a psychotropic medication regimen that has not been consistent for one month
  • Presence of diabetes mellitus or any current unstable medical illness or condition that represents a contraindication to taking glucocorticoids (this will be determined by history and/or abnormal laboratory findings at medical clearance)
  • Unwillingness to discontinue other specialized psychotherapy for PTSD during the 11 weeks of study treatment and the 3 month follow-up (Self-help (non-trauma focused) groups or supportive counseling can be continued but not initiated)
  • Pregnant women or those planning to become pregnant within the study period will not be enrolled. Female participants must agree to use an effective method of birth control (i.e., oral contraceptive, Norplant, diaphragm, condom, or spermicide, abstinence) during the course of the study to ensure they do not become pregnant during the course of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01525680

Contacts
Contact: Rachel Yehuda, PhD 718-741-4000 ext 6964 rachel.yehuda@va.gov

Locations
United States, New York
James J. Peters Veterans Affairs Medical Center Recruiting
Bronx, New York, United States, 10468
Contact: Rachel Yehuda, PhD       rachel.yehuda@va.gov   
Sponsors and Collaborators
Bronx VA Medical Center
United States Department of Defense
Investigators
Principal Investigator: Rachel Yehuda, PhD James J Peters VAMC/Mount Sinai School of Medicine
  More Information

Responsible Party: Rachel Yehuda, MHPCCD, Bronx VA Medical Center
ClinicalTrials.gov Identifier: NCT01525680     History of Changes
Other Study ID Numbers: YEH-09-087
Study First Received: February 1, 2012
Last Updated: November 27, 2013

Keywords provided by Rachel Yehuda, Bronx VA Medical Center:
PTSD

Additional relevant MeSH terms:
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders
Mental Disorders
Hydrocortisone 17-butyrate 21-propionate
Cortisol succinate
Hydrocortisone acetate
Hydrocortisone
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on May 25, 2017